A Phase II, Open-label, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal and Acral Melanoma Who Had Not Previously Received Systemic Therapy
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs IBI 363 (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Innovent Biologics
- 03 Feb 2025 New trial record